{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/cellulitis-acute/management/management/","result":{"pageContext":{"chapter":{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management","depth":2,"htmlHeader":"<!-- begin field 06baabb5-d3ef-4440-85f1-04c358eaa2fa --><h2>Scenario: Management of acute cellulitis</h2><!-- end field 06baabb5-d3ef-4440-85f1-04c358eaa2fa -->","summary":"Covers the management of acute cellulitis in primary care.","htmlStringContent":"<!-- begin item a0b4a85f-e5f3-4ea7-be40-dfbea45dd281 --><!-- begin field 654f4bdc-3d5a-4f21-b4f8-acbd00873bf6 --><p>From age 1 month onwards.</p><!-- end field 654f4bdc-3d5a-4f21-b4f8-acbd00873bf6 --><!-- end item a0b4a85f-e5f3-4ea7-be40-dfbea45dd281 -->","topic":{"id":"c0841d82-0a64-5b27-81dc-9a825d85f1bf","topicId":"6db61277-29ef-49cc-bad1-d0d78d0afc10","topicName":"Cellulitis - acute","slug":"cellulitis-acute","lastRevised":"Last revised in January 2021","chapters":[{"id":"84376fdb-da2b-561d-bb40-28b5b1a7e975","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"bdf35905-533d-5cb1-bd18-9c1575427a25","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"d6c8c4bd-9395-5840-83c7-67ddfeabdf85","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"59d003f6-dd50-5136-b5c2-c2ea4e4b6f01","slug":"changes","fullItemName":"Changes"},{"id":"f79ca51e-9432-56b1-95de-92ed6133be2b","slug":"update","fullItemName":"Update"}]},{"id":"05002b30-8200-5ccf-b9da-7c96acdb65bd","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"fefb70b6-1d32-5e70-afc6-291fa40b3137","slug":"goals","fullItemName":"Goals"},{"id":"cf84220a-f381-5ca1-aa76-ffb99c4959f6","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"aa32cbb7-29d6-58b6-bcde-7702767672ec","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"7e039433-2afe-5980-93f0-c20c41976610","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d1411fdd-dc83-5f20-9fa4-ad67b69c195a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"ce40a600-51e8-5b3a-86c2-d127f03c16eb","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ff60c523-3d6f-5766-8508-98e8cdcf08f5","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8e8cfe4a-13f2-573c-ab45-7231016746c4","slug":"definition","fullItemName":"Definition"},{"id":"2b7befe3-0fef-5d4e-b00d-bad6742fb93c","slug":"causes","fullItemName":"Causes"},{"id":"96971948-f52b-561c-84f8-8600f3eff2d4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"4749dc8a-3f24-5e65-a0a3-5d7665ef3085","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"ad3d41f6-595b-505c-b020-918f0e086d3f","slug":"complications","fullItemName":"Complications"},{"id":"82ccb916-06d4-5b29-91e4-90005f3db942","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"7305e6df-9b2c-5584-9412-54564432e382","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"8625eea6-53ec-5348-befa-a609ea64590f","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"273b1216-536e-59b4-8c39-547a97824ffa","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","fullItemName":"Management","slug":"management","subChapters":[{"id":"195394ca-067a-5cf3-bc4d-52a189d2cba6","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"4426193a-52c1-59b9-9222-77fb7169a3d1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"78de19b8-8e80-551f-8112-456ce2e25bb0","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"73060223-dd90-59da-bae3-c706b5d24298","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"83f47301-e112-5f78-a79a-5c03a9de9537","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"b7240858-fbcc-5f20-8dcd-19f0b7221ac4","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"07828388-33ed-5e04-90b7-28a76fa26c6e","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"4600d0c1-4cd1-51ee-87a0-b660f0fa2165","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"0c0b7a3f-11e4-5b00-bd21-b66e49f9ad77","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"29987f8b-20b6-5c1f-8d23-183b415a04fb","slug":"analgesia","fullItemName":"Analgesia"}]},{"id":"4b09dc1a-8268-50d6-a164-227a73b3556e","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"d49b86e1-77b2-58e6-82c0-ea0aa7ee74ed","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"fe910063-69df-5218-bb78-36f5863db2a1","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"129f5233-2934-55ad-a561-4eb37861dc10","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"74d5b6b4-ef9d-5fc4-b41b-656b81a7ded8","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"44402335-ffeb-5e14-9e77-bb8278ef43d6","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"04d7d640-f586-53d9-ac59-804c10dd593d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c50af1ff-f157-5023-92b4-aa07b1c28d76","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"68b86e3a-ee13-5ccd-9df0-a5c70c553251","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"08b4489d-8f61-5555-a73a-50f9a3504bd6","slug":"admission-referral","fullItemName":"Admission and referral","depth":3,"htmlHeader":"<!-- begin field ef4e39c2-8642-4e28-bde7-aa3400c85b14 --><h3>When should I admit or refer a person with cellulitis?</h3><!-- end field ef4e39c2-8642-4e28-bde7-aa3400c85b14 -->","summary":null,"htmlStringContent":"<!-- begin item 6e9e5cf1-3d86-4a0e-874c-aa3400c85ab0 --><!-- begin field b7afc890-2f03-4968-aaf2-aa3400c85b14 --><ul><li><strong>Arrange urgent hospital admission if the person:</strong><ul><li>Has Class IV cellulitis (sepsis or severe life-threatening infection, such as necrotizing fasciitis).</li><li>Has Class III cellulitis (significant systemic upset, such as acute confusion, tachycardia, tachypnoea, hypotension, or unstable comorbidities, or a limb-threatening infection due to vascular compromize). </li><li>Has severe or rapidly deteriorating cellulitis (for example extensive areas of skin).</li><li>Is very young (under 1 year of age) or frail.</li><li>Is immunocompromized.</li><li>Has significant lymphoedema.</li><li>Has facial cellulitis (unless very mild).</li><li>Has suspected orbital or periorbital cellulitis (admit to ophthalmology).</li><li>Has Class II cellulitis (systemically unwell or systemically well but with a comorbidity).<ul><li>Admission may not be necessary if the facilities and expertise are available in the community to give intravenous antibiotics and monitor the person (check local guidelines).</li></ul></li><li>Has symptoms or signs suggesting a more serious illness or condition (such as osteomyelitis, or septic arthritis).</li></ul></li><li><strong>Consider referring people to hospital, or seek specialist advice, if they:</strong><ul><li>Are severely unwell. </li><li>Have infection near the eyes or nose (including periorbital cellulitis).</li><li>Could have uncommon pathogens, for example, after a penetrating injury, exposure to water-borne organisms, or an infection acquired outside the UK.</li><li>Have spreading infection that is not responding to an oral antibiotic.</li><li>Have lymphangitis.</li><li>Cannot take oral antibiotics (exploring locally available options for giving intravenous antibiotics at home or in the community, rather than in hospital, where appropriate).</li></ul></li><li><strong>For cellulitis resulting from a wound contaminated with fresh water or sea water:</strong><ul><li>Seek specialist advice from a medical microbiologist.</li></ul></li><li><strong>Seek specialist advice or consider admission, depending on clinical judgement, if:</strong><ul><li>There is continuing or deteriorating systemic signs, with or without deteriorating local signs, after 2–3 days of <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#primary-care-management\">treatment</a>.</li><li>Symptoms are not improving (or are worsening) after 14 days of <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#primary-care-management\">treatment</a>.</li></ul></li><li><strong>If a person has recurrent episodes of cellulitis </strong>(more than two episodes at the same site within one year), consider routine referral to secondary care for advice on the use of prophylactic antibiotics.</li></ul><!-- end field b7afc890-2f03-4968-aaf2-aa3400c85b14 --><!-- end item 6e9e5cf1-3d86-4a0e-874c-aa3400c85ab0 -->","subChapters":[{"id":"7c80d9c3-d305-532c-a359-08ab21e9e899","slug":"basis-for-recommendation-ce0","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 040c547c-9bc1-414f-96aa-aa3400c85b18 --><h4>Basis for recommendation</h4><!-- end field 040c547c-9bc1-414f-96aa-aa3400c85b18 -->","summary":null,"htmlStringContent":"<!-- begin item ce060951-5ca5-493c-9d1f-aa3400c85b18 --><!-- begin field 9fcd79b9-4874-4e7e-a7ec-aa3400c85b18 --><p>These recommendations are based largely on the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Cellulitis, erysipelas, and necrotising fasciitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>], the British Lymphology Society <em>Consensus Document on the Management of Cellulitis in Lymphoedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Cellulitis and erysipelas: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE, 2019a</a>], and on expert opinion in review articles on cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Shriner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Bystritsky, 2018</a>].</p><h5>Urgent admission to hospital</h5><ul><li>Most people who are admitted to secondary care will require intravenous (IV) antibiotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].<ul><li>Severe localized infection or systemic features (which may indicate the development of bacteraemia) can be life threatening (for example if they progress to necrotizing fasciitis).</li><li>Certain groups of people (for example the very young and old, and people with comorbidities) are more vulnerable to life-threatening infection, so they require a lower threshold for admission.</li><li>People with cellulitis affecting anatomical areas where the consequence of tissue damage would be particularly critical (for example facial cellulitis and periorbital cellulitis) require immediate assessment.<ul><li>The CREST guideline recommends urgent referral to ophthalmology for people with suspected orbital or periorbital cellulitis, as it is vital to distinguish between the two due to potential complications from orbital cellulitis (decreased ocular motility, decreased visual acuity and cavernous sinus thrombosis) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].</li></ul></li></ul></li></ul><h5>IV antibiotics in the community</h5><ul><li>Certain groups of people with cellulitis can be treated in the community with IV antibiotics followed by a course of oral antibiotics, provided there is an organized service in place to administer the treatment and monitor the person [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].<ul><li>This includes people who are systemically ill with stable comorbidities that are unlikely to complicate treatment, and people who are systemically well but have one or more comorbidities that may complicate or delay the resolution of cellulitis (for example morbid obesity, peripheral arterial disease, or chronic venous insufficiency).</li><li>CKS advises that local guidelines are followed in areas where an outpatient parenteral antibiotic therapy (OPAT) service exists.</li></ul></li><li>A Cochrane systematic review on interventions for cellulitis and erysipelas (search date: May 2010) suggests the need for further investigation into the efficacy of oral antibiotics compared with IV antibiotics as there are only a small number of studies comparing the two [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Kilburn et al, 2010</a>]. Evidence from a subsequent prospective randomized non-inferiority trial (n = 47) suggests that oral antimicrobials are as effective as parenteral antimicrobials for the treatment of uncomplicated cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Aboltins, 2015</a>].</li></ul><h5>Referral for people with recurrent cellulitis to consider antibiotic prophylaxis</h5><ul><li>The recommendation to consider specialist referral for people with recurrent cellulitis is based on limited and conflicting evidence to support the routine use of prophylactic antibiotics for these people.<ul><li>Expert opinion in the CREST guideline is that antibiotic prophylaxis should be considered in people who have had at least two episodes of cellulitis at the same site, but acknowledges that this is based on weak and inconclusive evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>]. In addition, the British Lymphology Society and the PCDS recommend considering antibiotic prophylaxis in people with lymphoedema who have 2 or more attacks of cellulitis per year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>].</li><li>A US guideline <em>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update </em>published by the Infectious Diseases Society of America recommends considering prophylactic antibiotics in people who have had 3–4 episodes of cellulitis per year, despite attempts to treat or control predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Stevens et al, 2014</a>].</li><li>A systematic review and meta-analysis identified five randomized controlled trials (RCTs, n = 535) that assessed the efficacy of antibiotic prophylaxis in preventing recurrent cellulitis compared with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Oh et al, 2014</a>].<ul><li>The evidence showed that antibiotic prophylaxis significantly reduced the number of episodes of recurrent cellulitis.</li><li>In the antibiotic prophylaxis group, 44 of 260 people had an episode of cellulitis compared with 97 of 275 people in the placebo group (risk ratio 0.46; 95% CI 0.26 to 0.79, p value not available).</li><li>These results should be interpreted with caution, however, as there was heterogeneity between the studies regarding the antibiotics used, route of administration, number of recurrences of cellulitis at study entry, and study quality.</li></ul></li><li>A small, double-blind RCT (n = 123) assessed whether a 6-month course of prophylactic low-dose penicillin prescribed after only one episode of cellulitis could prevent further episodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UK Dermatology Clinical Trials Network's PATCH trial team et al, 2012</a>].<ul><li>The evidence showed that antibiotic treatment reduced the risk of recurrence by 47%, but the result was not statistically significant (95% CI 0.26 to 1.07; p = 0.08).</li></ul></li></ul></li></ul><!-- end field 9fcd79b9-4874-4e7e-a7ec-aa3400c85b18 --><!-- end item ce060951-5ca5-493c-9d1f-aa3400c85b18 -->","subChapters":[]}]},{"id":"c6fac8d9-5fe6-50c7-828c-35ceea0722c4","slug":"primary-care-management","fullItemName":"Primary care management","depth":3,"htmlHeader":"<!-- begin field 9698e602-6fe3-43c5-a5dc-c43b9f281fff --><h3>How should I manage acute cellulitis in primary care?</h3><!-- end field 9698e602-6fe3-43c5-a5dc-c43b9f281fff -->","summary":null,"htmlStringContent":"<!-- begin item 146ef4ae-b1e6-4e5c-a3dd-29698b8320aa --><!-- begin field 93467ae7-7122-431c-bf73-58763b0186a7 --><ul><li><strong>For people with Class I cellulitis (no signs of systemic toxicity and no uncontrolled comorbidities):</strong><ul><li><strong>Prescribe a high-dose oral <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#oral-antibiotics-in-primary-care\">antibiotic treatment</a>.</strong><ul><li>Before treatment, draw around the extent of the infection with a permanent marker pen for future comparison and to track the spread of infection. This may be difficult in people with lymphoedema as the rash is often blotchy.</li></ul></li><li><strong>Advise the person to:</strong><ul><li>Take paracetamol or ibuprofen for pain and fever. For detailed information on prescribing these analgesics, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/analgesia-mild-to-moderate-pain/\">Analgesia - mild-to-moderate pain</a>.</li><li>Drink adequate fluids.</li><li>Seek immediate medical advice if antibiotics are not tolerated, the cellulitis becomes worse (there may be an increase in the redness in the first 24–48 hours of treatment possibly due to release of toxins), or if systemic symptoms develop or worsen.</li><li>Elevate the leg for comfort and to relieve oedema (where applicable).</li><li>Avoid the use of compression garments during acute cellulitis.</li></ul></li><li><strong>Manage any underlying <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/risk-factors/\">risk factors</a> for cellulitis.</strong><ul><li>Manage breaks in the skin, for example, due to eczema, tinea pedis, or leg ulcers, which may become a portal of entry for organisms. See the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/eczema-atopic/\">Eczema - atopic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/\">Venous eczema and lipodermatosclerosis</a>, <a class=\"topic-reference external-reference\" href=\"/topics/fungal-skin-infection-foot/\">Fungal skin infection - foot</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/leg-ulcer-venous/\">Leg ulcer - venous</a> for management information. </li><li>Manage venous insufficiency. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/venous-eczema-lipodermatosclerosis/\">Venous eczema and lipodermatosclerosis</a> for management information.  </li><li>Consider referring people with lymphoedema to a specialist clinic.</li><li>Liaise with a district nurse if there is skin blistering, broken skin, exudate, or venous ulceration.</li></ul></li><li><strong>Identify and manage <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/risk-factors/\">comorbidities</a> (such as diabetes mellitus) that may cause the cellulitis to spread rapidly, or delay healing.</strong></li><li><strong>Advise on preventative measures to reduce the risk of recurrence, including:</strong><ul><li>Weight management if the person is obese. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li>The use of emollients to prevent dry skin and cracking.</li></ul></li><li><strong>Provide patient information on cellulitis. </strong>For example:<ul><li><a data-hyperlink-id=\"39bcd09d-46d7-463f-840c-aa3701805f4a\" href=\"http://www.bad.org.uk/shared/get-file.ashx?id=156&itemtype=document\">Cellulitis or erysipelas</a> published by the British Association of Dermatologists (BAD, <a data-hyperlink-id=\"129009c5-568e-464d-82e7-aa3701805f5c\" href=\"http://www.bad.org.uk/\">www.bad.org.uk</a>).</li><li><a data-hyperlink-id=\"f5d2b089-df60-44c3-b089-aa3701805fd3\" href=\"https://www.lymphoedema.org/index.php/cellulitis/about-cellulitis\">About cellulitis</a> published by the Lymphoedema Support Network (<a data-hyperlink-id=\"7cb48091-36a7-4188-b1a4-aa3701806081\" href=\"https://www.lymphoedema.org/\">www.lymphoedema.org</a>).</li><li><a data-hyperlink-id=\"61e5fab2-8590-4e62-8059-aa3701806101\" href=\"https://www.nhs.uk/conditions/cellulitis/\">Cellulitis</a> published by NHS (<a data-hyperlink-id=\"1fc9f1ab-b68f-4d81-bba7-aa3701806117\" href=\"https://www.nhs.uk/\">www.nhs.uk</a>).</li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#follow-up-in-primary-care\">Review</a> </strong><strong>the person after 2-3 days</strong> depending on clinical judgement, or if local symptoms deteriorate (such as redness or swelling beyond the initial presentation), have severe pain, or they develop systemic symptoms. </li></ul></li><li><strong>If a person has recurrent episodes of cellulitis </strong>(more than two episodes at the same site within one year), consider routine referral to secondary care for advice on the use of prophylactic antibiotics.</li></ul><!-- end field 93467ae7-7122-431c-bf73-58763b0186a7 --><!-- end item 146ef4ae-b1e6-4e5c-a3dd-29698b8320aa -->","subChapters":[{"id":"0908a165-fd2c-5bbc-aca5-9416c56089b3","slug":"basis-for-recommendation-df4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field cd4a2673-e856-4b73-80d9-92604e59bc71 --><h4>Basis for recommendation</h4><!-- end field cd4a2673-e856-4b73-80d9-92604e59bc71 -->","summary":null,"htmlStringContent":"<!-- begin item df4a275e-847a-43ef-8bdd-a5b6fd9948a8 --><!-- begin field 55e5c46a-4299-4e02-b47a-5af8a62d172c --><p>These recommendations are based largely on the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Cellulitis, erysipelas, and necrotising fasciitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>], the British Lymphology Society <em>Consensus Document on the Management of Cellulitis in Lymphoedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>], a Cochrane systematic review on <em>Interventions for the prevention of recurrent erysipelas and cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Dalal, 2017</a>], the National Institute for Health and Care Excellence (NICE) guideline <em>Cellulitis and erysipelas: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE, 2019a</a>], and expert opinion in review articles on cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Imohl et al, 2011</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Shriner, 2017</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">BMJ, 2018</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Bystritsky, 2018</a>].</p><h5>Giving advice and information</h5><ul><li>The recommended advice and information are consistent with advice in the CREST guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>] and are accepted as good clinical practice.</li><li>The rationale for elevating the leg is to reduce swelling and discomfort through the action of gravity.</li><li>The recommendation on avoiding compression garments is based on the CREST guideline<em> </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>] and the British Lymphology Society guideline  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>].</li></ul><h5>Referral for people with recurrent cellulitis to consider antibiotic prophylaxis</h5><ul><li>The recommendation to consider specialist referral for people with recurrent cellulitis is based on limited and conflicting evidence to support the routine use of prophylactic antibiotics for these people.<ul><li>Expert opinion in the CREST guideline is that antibiotic prophylaxis should be considered in people who have had at least two episodes of cellulitis at the same site, but acknowledges that this is based on weak and inconclusive evidence [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>]. In addition, the British Lymphology Society and the PCDS recommend considering antibiotic prophylaxis in people with lymphoedema who have 2 or more attacks of cellulitis per year [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>].</li><li>A US guideline <em>Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update </em>published by the Infectious Diseases Society of America recommends considering prophylactic antibiotics in people who have had 3–4 episodes of cellulitis per year, despite attempts to treat or control predisposing factors [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Stevens et al, 2014</a>].</li><li>A systematic review and meta-analysis identified five randomized controlled trials (RCTs, n = 535) that assessed the efficacy of antibiotic prophylaxis in preventing recurrent cellulitis compared with placebo [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Oh et al, 2014</a>].<ul><li>The evidence showed that antibiotic prophylaxis significantly reduced the number of episodes of recurrent cellulitis</li><li>In the antibiotic prophylaxis group, 44 of 260 people had an episode of cellulitis compared with 97 of 275 people in the placebo group (risk ratio 0.46; 95% CI 0.26 to 0.79, p value not available).</li><li>These results should be interpreted with caution, however, as there was heterogeneity between the studies regarding the antibiotics used, route of administration, number of recurrences of cellulitis at study entry, and study quality.</li></ul></li><li>A small, double-blind RCT (n = 123) assessed whether a 6-month course of prophylactic low-dose penicillin prescribed after only one episode of cellulitis could prevent further episodes [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">UK Dermatology Clinical Trials Network's PATCH trial team et al, 2012</a>].<ul><li>The evidence showed that antibiotic treatment reduced the risk of recurrence by 47%, but the result was not statistically significant (95% CI 0.26 to 1.07; p = 0.08).</li></ul></li></ul></li></ul><!-- end field 55e5c46a-4299-4e02-b47a-5af8a62d172c --><!-- end item df4a275e-847a-43ef-8bdd-a5b6fd9948a8 -->","subChapters":[]}]},{"id":"49d595da-4098-58a3-8ede-d4fb1a0cd7ad","slug":"oral-antibiotics-in-primary-care","fullItemName":"Oral antibiotics in primary care","depth":3,"htmlHeader":"<!-- begin field 50e59bf2-10db-426f-b8f0-b5bcd03238c2 --><h3>Which oral antibiotics should I prescribe?</h3><!-- end field 50e59bf2-10db-426f-b8f0-b5bcd03238c2 -->","summary":null,"htmlStringContent":"<!-- begin item ddd7e281-363b-4e05-afd4-8a70e20b8a90 --><!-- begin field 5df4f263-8302-428e-b23d-74d84e24acab --><p><strong>Before treatment, mark the area of cellulitis, if possible. Draw around the extent of the infection with a permanent marker pen for future comparison and to track the spread of infection. This may be difficult in people with lymphoedema as the rash is often blotchy.</strong></p><ul><li><strong>When choosing an antibiotic, take into account:</strong><ul><li>The severity of symptoms.</li><li>The site of infection (for example, near the eyes or nose).</li><li>The risk of uncommon pathogens (for example, from a penetrating injury, after exposure to water-borne organisms, or an infection acquired outside the UK).</li><li>Previous microbiological results from a swab.</li><li>The person's meticillin-resistant Staphylococcus aureus (MRSA) status if known.</li></ul></li><li><strong>For adults with Class I cellulitis (no signs of systemic toxicity and no uncontrolled comorbidities):</strong><ul><li>Prescribe flucloxacillin 500–1000 mg four times daily for 5–7 days. If this is unsuitable, or the person has a penicillin allergy, prescribe either:<ul><li>Clarithromycin 500 mg twice daily for 5–7 days.</li><li>Doxycycline 200 mg on the first day then 100 mg once daily, for a total of 5–7 days.</li><li>Erythromycin (in pregnancy) 500 mg four times daily for 5–7 days.</li></ul></li></ul></li><li><strong>For adults with infection near the eyes or nose who do not require <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#admission-referral\">admission or referral</a>:</strong><ul><li>Prescribe co-amoxiclav 500/125 mg three times a day for 7 days. If this is unsuitable, or the person has a penicillin allergy, prescribe:<ul><li>Clarithromycin 500 mg twice daily for 5–7 days with metronidazole 400 mg three times daily for 7 days.</li></ul></li></ul></li><li><strong>For adults with known lymphoedema who develop cellulitis but do not require <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#admission-referral\">admission or referral</a>:</strong><ul><li>Prescribe amoxicillin 500 mg three times daily.<ul><li>If there is any evidence of <em>Staphylococcus aureus </em>infection, for example, folliculitis, pus formation, or crusted dermatitis, prescribe flucloxacillin 500 mg four times a day in addition to amoxicillin, or as an alternative.</li><li>If the person has a penicillin allergy, prescribe clarithromycin 500 mg twice daily.</li></ul></li><li>Continue antibiotic treatment until all signs of acute inflammation have resolved. The course of antibiotics should be for no less than 14 days from the time a definite clinical response is observed.<ul><li>Skin changes (such as discolouration) may persist for months or longer following severe cellulitis and do not necessarily require ongoing antibiotics.</li></ul></li></ul></li><li><strong>For children aged 1 month and over with Class I cellulitis: </strong><ul><li><strong>Prescribe flucloxacillin</strong> for 5–7 days (aged 1 month to 1 year, 62.5–125 mg four times daily; aged 2 to 9 years, 125–250 mg four times daily; aged 10-17 years, 250–500 mg four times daily). If this is unsuitable prescribe:<ul><li><strong>Co-amoxiclav</strong> for 5–7 days (aged 1–11 months, 0.25 ml/ kg of 125/31 suspension three times a day [doubled dose in severe infection]; aged 1–5 years, 0.25 ml/kg or 5 ml of 125/31 suspension three times a day [dose doubled in severe infection]; aged 6 –11 years, 0.15 ml/kg or 5 ml of 250/62 suspension three times a day [dose doubled in severe infection]; aged 12–17 years, 250/125 mg or 500/125 mg three times a day).</li></ul></li><li><strong>If the person has a <em>true </em>penicillin allergy, </strong>prescribe:<ul><li><strong>Clarithromycin</strong> for 5–7 days (under 8 kg, 7.5 mg/kg twice a day; 8–11 kg, 62.5 mg twice a day; 12-19 kg, 125 mg twice a day; 20-29 kg, 187.5 mg twice a day; 30–40 kg, 250 mg twice a day; 12–17 years, 250–500 mg twice a day) or</li><li><strong>Erythromycin</strong> (in pregnancy) 250–500 mg four times a day for 5–7 days.</li></ul></li></ul></li><li><strong>For children aged 1 month and over with infection near the eyes or nose, consider seeking specialist advice and prescribe:</strong><ul><li><strong>Co-amoxiclav</strong> three times daily for 7 days. If this is unsuitable, or the person has a penicillin allergy, prescribe either:<ul><li><strong>Clarithromycin</strong> twice daily for 7 days.</li><li><strong>Clarithromycin <em>plus</em> metronidazole</strong> twice daily for 7 days if the presence of anaerobes is suspected (aged 1 month, 7.5 mg/kg twice a day; aged 2 months to 11 years, 7.5 mg/kg three times a day [maximum per dose 400 mg]; aged 12–17 years, 400 mg three times a day).</li></ul></li></ul></li><li><strong><a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#follow-up-in-primary-care\">Review</a> the person after 2-3 days depending on clinical judgement, or if local symptoms deteriorate (such as redness or swelling beyond the initial presentation), have severe pain, or they develop systemic symptoms. </strong></li><li><strong>See the sections on <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/amoxicillin/\">Amoxicillin</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/clarithromycin/\">Clarithromycin</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/co-amoxiclav/\">Co-amoxiclav</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/doxycycline/\">Doxycycline</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/erythromycin/\">Erythromycin</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/flucloxacillin/\">Flucloxacillin</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/prescribing-information/metronidazole/\">Metronidazole</a> for detailed prescribing information.</strong></li></ul><!-- end field 5df4f263-8302-428e-b23d-74d84e24acab --><!-- end item ddd7e281-363b-4e05-afd4-8a70e20b8a90 -->","subChapters":[{"id":"b0b20a4f-7862-5b96-a6a4-87ddcb715d67","slug":"basis-for-recommendation-8c9","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 2ef4cfd0-f7b8-4b64-b27c-a0aee6041690 --><h4>Basis for recommendation</h4><!-- end field 2ef4cfd0-f7b8-4b64-b27c-a0aee6041690 -->","summary":null,"htmlStringContent":"<!-- begin item 8c9ba6bd-bf33-4c21-8bd2-76c2438e172e --><!-- begin field d08a722b-aa05-454e-a96c-3024f2210dfc --><h5>Recording the extent of the cellulitis</h5><ul><li><p>This recommendation is based on expert opinion in the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the British Lymphology Society <em>Consensus Document on the Management of Cellulitis in Lymphoedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>], the Primary Care Dermatology Society (PCDS) guideline <em>Cellulitis, erysipelas, and necrotising fasciitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PCDS, 2018</a>], and in review article on cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Phoenix et al, 2012</a>].</p></li></ul><h5>Choice of antibiotics and duration of treatment</h5><ul><li>The recommended choice of antibiotics is based on the National Institute for Health and Care Excellence (NICE) guideline <em>Cellulitis and erysipelas: antimicrobial prescribing </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE, 2019a</a>], <em>the </em>Public Health England (PHE) <em>Summary of antimicrobial prescribing guidance – managing common infections: PHE context, references and rationales for Clinical Commissioning Groups, Commissioning Support Units and Primary Care Providers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PHE, 2018b</a>] and a joint National Institute for Health and Care Excellence (NICE) and PHE <em>Summary of antimicrobial prescribing guidance – managing common infections</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE and PHE, 2019</a>]. The PHE summary is based largely on the CREST guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], and trial evidence.<ul><li>Most cases of cellulitis are caused by beta-haemolytic <em>Streptococci </em>or <em>Staphylococcus aureus</em>, so empirical treatment should be active against these organisms [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PHE, 2018b</a>].<ul><li>Flucloxacillin is a relatively narrow-spectrum antibiotic licensed for the treatment of cellulitis and other soft tissue infections [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">ABPI, 2018a</a>]. At high doses, it is active against the large majority of staphylococcal and streptococcal species that cause cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].</li><li>Clarithromycin is an erythromycin derivative with slightly greater activity than erythromycin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Joint Formulary Committee, 2019</a>] and is recommended as an alternative to flucloxacillin if the person is penicillin allergic [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>]. A systematic review of 15 studies (9 in people with cellulitis or erysipelas) found that the efficacy of treatment of cellulitis or erysipelas was similar with a beta-lactam and a macrolide. The risk of adverse effects was also similar for both groups of antibiotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Ferreira, 2016</a>].</li><li>Doxycycline 200 mg is recommended as an alternative if the person is penicillin allergic and taking statins (for example simvastatin or atorvastatin) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE and PHE, 2019</a>], because there is an increased risk of myopathy if macrolides are taken with cytochrome CYP3A4 inhibitors, such as simvastatin and atorvastatin [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2008</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">MHRA, 2014</a>]. </li><li>Co-amoxiclav is recommended for empirical treatment of facial cellulitis as it has a broader spectrum of activity than flucloxacillin and also covers anaerobes and other less common causes of facial cellulitis [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Fisher, 2002</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">PHE, 2018b</a>]. PHE does not make any recommendations for people who are penicillin allergic, so CKS recommends seeking advice from a microbiologist.</li></ul></li></ul></li><li>The recommendation for adults with known lymphoedema who develop cellulitis but do not require admission or referral is based on the British Lymphology Society guideline [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>].<br> </li></ul><!-- end field d08a722b-aa05-454e-a96c-3024f2210dfc --><!-- end item 8c9ba6bd-bf33-4c21-8bd2-76c2438e172e -->","subChapters":[]}]},{"id":"56d6b209-4a63-5051-958b-060d678ad09d","slug":"follow-up-in-primary-care","fullItemName":"Follow up in primary care","depth":3,"htmlHeader":"<!-- begin field a42bb13a-7a78-41e7-981d-9a469f316af1 --><h3>How should I follow up a person on oral antibiotic treatment?</h3><!-- end field a42bb13a-7a78-41e7-981d-9a469f316af1 -->","summary":null,"htmlStringContent":"<!-- begin item 37d136bd-7363-4e7b-9074-25791a6a60f3 --><!-- begin field 03400316-ccae-4944-8cb4-8c8434c3fe9e --><ul><li><strong>Review the person after 2-3 days</strong> depending on clinical judgement, or if local symptoms deteriorate (such as redness or swelling beyond the initial presentation), have severe pain, or they develop systemic symptoms. <ul><li><strong>If there is continuing or deteriorating systemic signs, with or without deteriorating local signs, after 2-3 days of antibiotic treatment:</strong><ul><li>Seek specialist advice or consider admission, depending on clinical judgement.</li></ul></li><li><strong>If there is no substantial improvement after 7 days </strong>of <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/management/management/#oral-antibiotics-in-primary-care\">first-line oral antibiotic treatment</a> and the person is systemically well:<ul><li>Assess adherence to treatment, and continue the first-line oral antibiotic for a further 7 days. </li><li>If a swab result is available, use sensitivity results to guide treatment.</li></ul></li><li><strong>If symptoms are not improving (or are worsening) after 14 days:</strong><ul><li>Exclude <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/diagnosis/differential-diagnosis/\">differential diagnoses</a> or <a class=\"topic-reference internal-reference\" href=\"/topics/cellulitis-acute/background-information/risk-factors/\">complicating conditions</a> (such as diabetes mellitus) that may cause the cellulitis to spread rapidly, or delay healing.</li><li>Consider admission or seeking specialist advice, depending on clinical judgement.</li></ul></li></ul></li></ul><!-- end field 03400316-ccae-4944-8cb4-8c8434c3fe9e --><!-- end item 37d136bd-7363-4e7b-9074-25791a6a60f3 -->","subChapters":[{"id":"2e92232f-28b7-54b8-87f5-d8cd2e5a0e82","slug":"basis-for-recommendation-897","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 4e1292e0-e48c-401c-955f-0838f68579a2 --><h4>Basis for recommendation</h4><!-- end field 4e1292e0-e48c-401c-955f-0838f68579a2 -->","summary":null,"htmlStringContent":"<!-- begin item 8973e49a-5e76-4b7c-9d22-be6423f1e28c --><!-- begin field c7209eb4-a650-4005-b622-458aab9dbe64 --><p>These recommendations are based largely on the Clinical Resource Efficiency Support Team (CREST) <em>Guidelines on the management of cellulitis</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>], the British Lymphology Society <em>Consensus Document on the Management of Cellulitis in Lymphoedema</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>], and a joint National Institute for Health and Care Excellence (NICE) and Public Health England (PHE) <em>Summary of antimicrobial prescribing guidance – managing common infections</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE and PHE, 2019</a>], and the NICE guideline <em>Cellulitis and erysipelas: antimicrobial prescribing</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE, 2019a</a>].</p><h5>Duration of antibiotic treatment</h5><ul><li>There is a lack of evidence on the optimal duration of antibiotic treatment. Expert opinion in the CREST guideline is that uncomplicated cases usually respond to 1–2 weeks of treatment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">CREST, 2005</a>].</li><li>If there has been a slow response to treatment with oral antibiotics, expert opinion in the joint NICE and PHE guideline is that the antibiotic course can be extended for a further 7 days [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">NICE and PHE, 2019</a>].</li></ul><h5>No improvement after two weeks of antibiotics</h5><ul><li>CKS could not find any evidence on the management of people who are not responding after 2 weeks of oral antibiotic treatment. The recommendations to exclude differential diagnoses or complicating conditions and to consider admission or seeking specialist advice are pragmatic, based on what CKS considers to be good clinical practice. In addition:<ul><li>The British Lymphology Society guideline recommends hospital admission if the person develops signs of septicaemia, or fails to respond to oral antibiotics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">British Lymphology Society, 2016</a>].</li><li>Expert opinion in a review article on cellulitis is that failure to improve with appropriate first-line antibiotics should prompt consideration for resistant organisms, differential diagnoses of cellulitis, or underlying complicating conditions, such as immunosuppression, chronic liver disease, or chronic kidney disease [<a class=\"bibliography-reference internal-reference\" href=\"/topics/cellulitis-acute/references/\">Raff, 2016</a>].</li></ul></li></ul><!-- end field c7209eb4-a650-4005-b622-458aab9dbe64 --><!-- end item 8973e49a-5e76-4b7c-9d22-be6423f1e28c -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}